MicroRNA与多发性骨髓瘤化疗耐药的研究进展

The development of MicroRNA and the chemoresistance of multiple myeloma

尽管众多新治疗方法的问世已显著提高了多发性骨髓瘤患者的生存周期，但由于耐药问题的出现，使得部分患者在治疗上面临着复发的严重挑战。微小RNA（microRNA，miRNA）是一类由19-25核苷酸组成的非编码RNA，其可作为基因表达的调节剂，在疾病的发生中起着重要作用。越来越多的研究证据表明，miRNA可能在肿瘤细胞的发生、增殖、凋亡及耐药中发挥着重要作用。因而对miR-27a、miR-21、miR-202、miR-221与miR-222与多发性骨髓瘤耐药机制进行研究，克服多发性骨髓瘤耐药问题提供新的思路。

Although many of new treatments have significantly increased the survival of patients with multi- pie myeloma,some patients are still facing serious challenges in the treatment due to the emergence of drug resist- ance. MicroRNA（miRNA）is a class of non-coding RNA consisting of 19-25 nucleotides. It can act as a modulator of gene expression ,and it plays an important role in the development of diseases. More and more research evidence sug- gests that miRNAs may play an important role in oncogenesis,the proliferation and apoptosis of tumor cells, and drug resistance. Here we reviewed the role of miR-27a, miR-21, miR-202,miR-221 ,and miR-222 in the chemoresistance of multiple myeloma,in the hope to provide new ideas to overcome the chemoresistance of multiple.